As India gears up for the upcoming festive season, analysts believe the stock market may hit record highs, driven by improving macroeconomic conditions, robust corporate earnings, and festive-driven consumption demand. The Nifty 50 and Sensex are already trading near all-time highs and may gain further ground with strong Q2 results and pre-election optimism on the horizon.

While large-cap sectors like banking, auto, and FMCG are expected to ride the consumption wave, pharma stocks are quietly emerging as a contrarian play. After underperforming over the last year, the pharmaceutical sector is showing signs of a turnaround, backed by improved USFDA clearance trends, stabilizing pricing pressures in the US generics market, and strong domestic demand.

Market experts suggest that investors looking to diversify should consider selective exposure to mid-cap and large-cap pharma names. Stocks with export exposure, especially in the API and formulation segments, could see strong earnings traction.

As festive spending boosts broader market sentiment, the combination of cyclical tailwinds and defensive positioning makes pharma a compelling contra bet — a sector poised to benefit from both global recovery and domestic resilience.

The Indian stock market is poised for a potential record-breaking rally during the upcoming festive season, supported by macroeconomic tailwinds, improved rural sentiment, and a strong corporate earnings outlook. Analysts project that indices like the Nifty 50 and Sensex could breach new highs, especially with favorable cues from inflation data, foreign fund inflows, and pre-election optimism.

Amid this bullish outlook, the pharmaceutical sector — which has largely underperformed since 2022 — is gaining traction as a contrarian investment theme. Experts suggest that pharma could stage a comeback, driven by several tailwinds: easing of pricing pressures in the US generics market, positive inspection outcomes from USFDA, rising healthcare expenditure, and a stable rupee.

Market participants recommend a stock-specific approach, focusing on companies with a strong R&D pipeline, regulatory compliance, and healthy balance sheets. Sun Pharma, Cipla, Dr. Reddy’s, Lupin, and selective midcaps like Alkem Labs and Syngene are being viewed as favorable bets.

Pharma offers an attractive risk-reward trade-off — a defensively positioned sector benefiting from secular trends, just as the broader market enters a high-beta festive phase. For long-term investors, it could serve as a hedge against volatility and a source of consistent earnings growth.